Ground-breaking Human Trial by Temple Therapeutics Solves 187-year-old Surgical Mystery

WALTHAM, Mass. - June 5, 2023 - PRLog -- Temple Therapeutics (http://www.templerx.com/), a biotechnology company pioneering a female-focused precision medicine approach, released the publication of its Phase 2 trial for the first pharmaceutical known as TTX333 (https://www.templerx.com/tissue-fibrosis) which shows the complete prevention of post-surgical adhesions in 93.3% of patients undergoing gynecological surgery. The company also revealed breakthrough findings on ovarian cancer (https://www.templerx.com/news/temple-therapeutics-reveals-breakthrough-findings-on-ovarian-cancer-at-aacr-2023) at the American Association for Cancer Research (AACR) 2023 conference, highlighting the company's commitment to revolutionizing women's health and its dedication to advancing precision medicine.

"When approved, TTX333 will be game-changing for millions of women undergoing pelvic and abdominal surgeries, such as endometriosis, hysterectomies, ovarian cancer, and c-sections each year," said Sanj Singh, CEO of Temple Therapeutics. "Temple is profoundly changing women's health, and we are excited about pioneering this new therapy through Phase 3 clinical trial to advance the therapy for commercial use in all gynecological surgeries, and eventually, to all general surgeries.

Rarely spoken about, adhesions (https://www.mdpi.com/2077-0383/11/6/1476) are one of the biggest challenges faced by women post-surgery, and its prevention has remained unsolved for 187 years, until now. Adhesions can affect the female reproductive organs, including ovaries and fallopian tubes, as well as the bowel, the area around the heart, joints (https://www.verywellhealth.com/arthrofibrosis-2548476), and hands. Moreover, the lack of awareness among patients regarding adhesions, combined with the associated surgical risks, has resulted in an upsurge of medico-legal claims.

"Adhesions can cause a range of problems, including infertility (https://www.linkedin.com/feed/hashtag/?keywords=infertility&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7051852374415458305), dyspareunia (https://www.linkedin.com/feed/hashtag/?keywords=dyspareunia&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7051852374415458305) (painful intercourse), pelvic pain (https://www.linkedin.com/feed/hashtag/?keywords=pelvicpain&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7051852374415458305), and bowel obstruction (https://www.linkedin.com/feed/hashtag/?keywords=bowelobstruction&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7051852374415458305)," said Dr. Rudy Leon de Wilde (https://uol.de/gynaekologie), author on this study and Chair of the Special Interest Adhesion Research Group of the European Society of Gynecological Endoscopy (ESGE) and the Anti-adhesions in Gynaecology Expert Panel-group (ANGEL). "Many of these go undiagnosed, and even when diagnosed, there is no effective solution other than more surgery, a self-defeating exercise as they reform in 90% of cases (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890766/)."

Dr. Antonio Gargiulo (https://www.linkedin.com/in/angargiulo/), author and reproductive endocrinologist and surgeon, Associate Professor of Obstetrics, Gynecology and Reproductive Biology (https://physiciandirectory.brighamandwomens.org/details/871/antonio-gargiulo-obstetrics_gynecology-boston-stratham) - Harvard Medical School, Center for Infertility and Reproductive Surgery and Medical Director of Gynecologic Robotic Surgery at Brigham and Women's Hospital, mentioned Temple's breakthrough as "a completely novel therapeutic approach to dealing with adhesions in the European Journal of Obstetrics and Gynecology and Reproductive Biology (https://www.ejog.org/action/showPdf?pii=S0301-2115%2823%2900122-7) on April 7, 2023.

All trademarks recognized.

#